Background Patients with severe aortic stenosis (AS) are at high risk of mortality, regardless of symptom status. Despite ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Transglutaminase 2 (TGM2) has ...

In-hospital mortality was significantly lower in patients aged 90 years or older treated with PCI compared with medical management.

Trials in AF and acute coronary syndrome were stopped early for futility, but there’s hope for factor XIa inhibitors given ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Revolutionary technologies like pulsed field ablation and structural heart therapies are driving rapid market expansion.